S
Sandra V. Navarra
Researcher at University of Santo Tomas
Publications - 116
Citations - 6315
Sandra V. Navarra is an academic researcher from University of Santo Tomas. The author has contributed to research in topics: Systemic lupus erythematosus & Lupus erythematosus. The author has an hindex of 28, co-authored 100 publications receiving 4786 citations. Previous affiliations of Sandra V. Navarra include University of Santo Tomas Hospital & St. Luke's Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra,Renato Guzman,Alberto E. Gallacher,Stephen B. Hall,Roger A. Levy,Renato E. Jimenez,Edmund K. Li,Mathew Thomas,Ho-Youn Kim,Manuel G. León,Coman Tanasescu,Eugeny L. Nasonov,Joung-Liang Lan,Lilia Pineda,Z. John Zhong,William W. Freimuth,Michelle A. Petri +16 more
TL;DR: The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus in a multicentre phase 3 study done in Latin America, Asia-Pacific, and eastern Europe.
Journal ArticleDOI
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven,Marta Mosca,George Bertsias,David A. Isenberg,Annegret Kuhn,Kristen Lerstrom,Martin Aringer,Hendrika Bootsma,Dimitrios T. Boumpas,Ian N. Bruce,Ricard Cervera,Ann E. Clarke,Nathalie Costedoat-Chalumeau,László Czirják,Ronald H. W. M. Derksen,Thomas Dörner,Caroline Gordon,Winfried Graninger,Frédéric Houssiau,Murat Inanc,Søren Jacobsen,David Jayne,A. Jedryka-Goral,A. Levitsky,Roger A. Levy,Xavier Mariette,Eric F Morand,Sandra V. Navarra,Irmgard Neumann,Anisur Rahman,Jozef Rovensky,Josef S Smolen,Carlos Vasconcelos,Alexandre E. Voskuyl,Anne Voss,Helena Zakharova,Asad Zoma,Matthias Schneider +37 more
TL;DR: Treating-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative and it is anticipated that ‘treating- to-target’ can and will be applicable to the care of patients with SLE.
Journal ArticleDOI
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn,Chak Sing Lau,Sandra V. Navarra,Worawit Louthrenoo,Aisha Lateef,Laniyati Hamijoyo,C Singgih Wahono,Shun Le Chen,O Jin,S. Morton,Alberta Hoi,Molla Huq,Mandana Nikpour,Eric F Morand +13 more
TL;DR: A definition of LLDAS has been generated, and preliminary validation demonstrates its attainment to be associated with improved outcomes in SLE.
Journal ArticleDOI
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi,Jorge Sánchez-Guerrero,Joan T. Merrill,Richard Furie,Dafna D. Gladman,Sandra V. Navarra,Ellen M. Ginzler,David D'Cruz,Andrea Doria,Simon Cooper,Z. John Zhong,Douglas R. Hough,William W. Freimuth,Michelle Petri +13 more
TL;DR: Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains and less worsening occurred in the haematological, immunological and renal domains.
Journal ArticleDOI
Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality.
Rupert W. Jakes,Sang Cheol Bae,Worawit Louthrenoo,Chi Chiu Mok,Sandra V. Navarra,Namhee Kwon +5 more
TL;DR: Prevalence, severity, and outcome across countries in the Asia‐Pacific region of systemic lupus erythematosus is described.